Fibroblast Growth Factor 23–Mediated Bone Disease

Endocrinology and Metabolism Clinics of North America

Volumn 46, Issue 1, 2017, Pages 19-39

  Gonciulea, Anda R ^a   Jan De Beur, Suzanne M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FGF23; Hyperphosphatemia; Hypophosphatemia; Osteomalacia; Rickets; Klotho

Indexed keywords

ALPHA KLOTHO PROTEIN; BUROSUMAB; CINACALCET; DENTIN MATRIX PROTEIN 1; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE I; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1C; GALLIUM DOTATATE GA 68; KLOTHO PROTEIN; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; NVPBGJ 398; OCTREOTIDE; PENTETREOTIDE IN 111; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHODIESTERASE I; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; PHOSPHATE; VITAMIN D;

ALBRIGHT SYNDROME; AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS 1; AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS 2; BONE DYSPLASIA; DIFFERENTIAL DIAGNOSIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; FAMILIAL TUMORAL CALCINOSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIC RICKETS; MISSENSE MUTATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENIC OSTEOMALACIA; OPEN STUDY; OSTEOGLOPHONIC DYSPLASIA; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RADIOFREQUENCY ABLATION; REVIEW; SEBACEOUS NEVUS; SIGNAL TRANSDUCTION; TUMOR CALCINOSIS; X LINKED HYPOPHOSPHATEMIC RICKETS; BONE DISEASE; METABOLISM;

BONE DISEASES; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; PHOSPHATES; SIGNAL TRANSDUCTION; VITAMIN D;

EID: 85007560468     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2016.09.013     Document Type: Review

References (98)

1. 1 Shimada, T., Muto, T., Urakawa, I., et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:8 (2002), 3179–3182.
2. 2 Kuro-o, M., Matsumura, Y., Aizawa, H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:6655 (1997), 45–51.
3. 3 Shimada, T., Kakitani, M., Yamazaki, Y., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:4 (2004), 561–568.
4. 4 Kurosu, H., Ogawa, Y., Miyoshi, M., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:10 (2006), 6120–6123.
5. Imura, A., Iwano, A., Tohyama, O., et al. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 565:1–3 (2004), 143–147.
6. 6 Chang, Q., Hoefs, S., van der Kemp, A.W., et al. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 310:5747 (2005), 490–493.
7. 7 Hu, M.C., Shi, M., Zhang, J., et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 24:9 (2010), 3438–3450.
8. 8 Forster, I.C., Hernando, N., Biber, J., et al. Proximal tubular handling of phosphate: A molecular perspective. Kidney Int 70:9 (2006), 1548–1559.
9. 9 Shimada, T., Hasegawa, H., Yamazaki, Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:3 (2004), 429–435.
10. 10 Krajisnik, T., Bjorklund, P., Marsell, R., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:1 (2007), 125–131.
11. 11 Ben-Dov, I.Z., Galitzer, H., Lavi-Moshayoff, V., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:12 (2007), 4003–4008.
12. 12 Brownstein, C.A., Adler, F., Nelson-Williams, C., et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A 105:9 (2008), 3455–3460.
13. 13 Olauson, H., Lindberg, K., Amin, R., et al. Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet, 9(12), 2013, e1003975.
14. 14 Yu, X., Sabbagh, Y., Davis, S.I., et al. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36:6 (2005), 971–977.
15. 15 Liu, S., Tang, W., Zhou, J., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:5 (2006), 1305–1315.
16. 16 Collins, M.T., Lindsay, J.R., Jain, A., et al. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D. J Bone Miner Res 20:11 (2005), 1944–1950.
17. 17 Scanni, R., vonRotz, M., Jehle, S., et al. The human response to acute enteral and parenteral phosphate loads. J Am Soc Nephrol 25:12 (2014), 2730–2739.
18. 18 Burnett, S.M., Gunawardene, S.C., Bringhurst, F.R., et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21:8 (2006), 1187–1196.
19. 19 Ito, N., Fukumoto, S., Takeuchi, Y., et al. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 25:6 (2007), 419–422.
20. 20 Quinn, S.J., Thomsen, A.R., Pang, J.L., et al. Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab 304:3 (2013), E310–E320.
21. 21 Lavi-Moshayoff, V., Wasserman, G., Meir, T., et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299:4 (2010), F882–F889.
22. 22 Burnett-Bowie, S.M., Henao, M.P., Dere, M.E., et al. Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res 24:10 (2009), 1681–1685.
23. 23 Saji, F., Shigematsu, T., Sakaguchi, T., et al. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 299:5 (2010), F1212–F1217.
24. Gutierrez, O.M., Smith, K.T., Barchi-Chung, A., et al. (1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. Clin J Am Soc Nephrol 7:1 (2012), 139–145.
25. 25 Imel, E.A., Gray, A.K., Padgett, L.R., et al. Iron and fibroblast growth factor 23 in X-linked hypophosphatemia. Bone 60 (2014), 87–92.
26. 26 Imel, E.A., Peacock, M., Gray, A.K., et al. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96:11 (2011), 3541–3549.
27. 27 Braithwaite, V., Prentice, A.M., Doherty, C., et al. FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol, 2012(1), 2012, 27.
28. 28 McCance, R.A., Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med 16:1 (1947), 33–46.
29. 29 Prader, A., Illig, R., Uehlinger, E., et al. Rickets following bone tumor. Helv Paediatr Acta 14 (1959), 554–565.
30. 30 Dadoniene, J., Miglinas, M., Miltiniene, D., et al. Tumour-induced osteomalacia: a literature review and a case report. World J Surg Oncol, 14(1), 2016, 4.
31. 31 Battoo, A.J., Salih, S., Unnikrishnan, A.G., et al. Oncogenic osteomalacia from nasal cavity giant cell tumor. Head Neck 34:3 (2012), 454–457.
32. 32 Sauder, A., Wiernek, S., Dai, X., et al. FGF23-associated tumor-induced osteomalacia in a patient with small cell carcinoma: a case report and regulatory mechanism study. Int J Surg Pathol 24:2 (2016), 116–120.
33. 33 Leaf, D.E., Pereira, R.C., Bazari, H., et al. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J Clin Endocrinol Metab 98:3 (2013), 887–891.
34. 34 Folpe, A.L., Fanburg-Smith, J.C., Billings, S.D., et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1 (2004), 1–30.
35. 35 Houang, M., Clarkson, A., Sioson, L., et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol 44:12 (2013), 2711–2718.
36. 36 Lee, J.C., Jeng, Y.M., Su, S.Y., et al. Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol 235:4 (2015), 539–545.
37. 37 Lee, J.C., Su, S.Y., Changou, C.A., et al. Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol, 2016, 2016, 137.
38. 38 Jiang, Y., Xia, W.B., Xing, X.P., et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res 27:9 (2012), 1967–1975.
39. 39 Hautmann, A.H., Hautmann, M.G., Kolbl, O., et al. Tumor-induced osteomalacia: an up-to-date review. Curr Rheumatol Rep, 17(6), 2015, 512.
40. 40 Jan de Beur, S.M., Tumor-induced osteomalacia. JAMA 294:10 (2005), 1260–1267.
41. 41 Jan de Beur, S.M., Streeten, E.A., Civelek, A.C., et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359:9308 (2002), 761–763.
42. 42 Jonsson, K.B., Zahradnik, R., Larsson, T., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:17 (2003), 1656–1663.
43. 43 Chong, W.H., Yavuz, S., Patel, S.M., et al. The importance of whole body imaging in tumor-induced osteomalacia. J Clin Endocrinol Metab 96:12 (2011), 3599–3600.
44. Breer, S., Brunkhorst, T., Beil, F.T., et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone 64 (2014), 222–227.
45. 45 Shane, E., Parisien, M., Henderson, J.E., et al. Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res 12:9 (1997), 1502–1511.
46. 46 Ogose, A., Hotta, T., Emura, I., et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol 30:2 (2001), 99–103.
47. 47 Hesse, E., Rosenthal, H., Bastian, L., Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med 357:4 (2007), 422–424.
48. 48 Geller, J.L., Khosravi, A., Kelly, M.H., et al. Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 22:6 (2007), 931–937.
49. 49 Seufert, J., Ebert, K., Muller, J., et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 345:26 (2001), 1883–1888.
50. 50 Paglia, F., Dionisi, S., Minisola, S., Octreotide for tumor-induced osteomalacia. N Engl J Med 346:22 (2002), 1748–1749 [author reply: 1748–9].
51. 51 Aono, Y., Yamazaki, Y., Yasutake, J., et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 24:11 (2009), 1879–1888.
52. 52 Carpenter, T.O., Imel, E.A., Ruppe, M.D., et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 124:4 (2014), 1587–1597.
53. 53 Imel, E.A., Zhang, X., Ruppe, M.D., et al. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 100:7 (2015), 2565–2573.
54. 54 Wohrle, S., Henninger, C., Bonny, O., et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res 28:4 (2013), 899–911.
55. 55 Colling M. Striking response of tumor-induced osteomalacia to the FGFR inhibitor NVP-BGJ398. ASBMR 2015 Annual Meeting; 2015; Washington State Convention Center. Seattle (WA), October 19–22, 2015.
56. 56 Bai, X., Miao, D., Xiao, S., et al. CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. J Clin Invest 126:2 (2016), 667–680.
57. 57 Alizadeh Naderi, A.S., Reilly, R.F., Hereditary disorders of renal phosphate wasting. Nat Rev Nephrol 6:11 (2010), 657–665.
58. 58 Beck, L., Soumounou, Y., Martel, J., et al. Pex/PEX tissue distribution and evidence for a deletion in the 3’ region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 99:6 (1997), 1200–1209.
59. 59 Liu, S., Guo, R., Simpson, L.G., et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278:39 (2003), 37419–37426.
60. 60 Lee, J.Y., Imel, E.A., The changing face of hypophosphatemic disorders in the FGF-23 era. Pediatr Endocrinol Rev 10:Suppl 2 (2013), 367–379.
61. 61 Polisson, R.P., Martinez, S., Khoury, M., et al. Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med 313:1 (1985), 1–6.
62. 62 Nehgme, R., Fahey, J.T., Smith, C., et al. Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 82:8 (1997), 2450–2454.
63. 63 Mughal, Z., Rickets in childhood. Semin Musculoskelet Radiol 6:3 (2002), 183–190.
64. 64 Pavone, V., Testa, G., Gioitta Iachino, S., et al. Hypophosphatemic rickets: etiology, clinical features and treatment. Eur J Orthop Surg Traumatol 25:2 (2015), 221–226.
65. 65 Quinlan, C., Guegan, K., Offiah, A., et al. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol 27:4 (2012), 581–588.
66. Petersen, D.J., Boniface, A.M., Schranck, F.W., et al. X-linked hypophosphatemic rickets: a study (with literature review) of linear growth response to calcitriol and phosphate therapy. J Bone Miner Res 7:6 (1992), 583–597.
67. 67 Carpenter, T.O., Imel, E.A., Holm, I.A., et al. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 26:7 (2011), 1381–1388.
68. 68 Connor, J., Olear, E.A., Insogna, K.L., et al. Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease. J Clin Endocrinol Metab 100:10 (2015), 3625–3632.
69. 69 Econs, M.J., Conventional therapy in adults with XLH improves dental manifestations, but not enthesopathy. J Clin Endocrinol Metab 100:10 (2015), 3622–3624.
70. 70 Yavropoulou, M.P., Kotsa, K., Gotzamani Psarrakou, A., et al. Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. Hormones (Athens) 9:3 (2010), 274–278.
71. 71 Liu, E.S., Carpenter, T.O., Gundberg, C.M., et al. Calcitonin administration in X-linked hypophosphatemia. N Engl J Med 364:17 (2011), 1678–1680.
72. 72 Alon, U.S., Levy-Olomucki, R., Moore, W.V., et al. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 3:3 (2008), 658–664.
73. 73 Yuan, B., Feng, J.Q., Bowman, S., et al. Hexa-D-arginine treatment increases 7B2*PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype. J Bone Miner Res 28:1 (2013), 56–72.
74. 74 Zivicnjak, M., Schnabel, D., Staude, H., et al. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab 96:12 (2011), E2097–E2105.
75. 75 Makitie, O., Toiviainen-Salo, S., Marttinen, E., et al. Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets. Horm Res 69:4 (2008), 212–220.
76. 76 ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:3 (2000), 345–348.
77. 77 Econs, M.J., McEnery, P.T., Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:2 (1997), 674–681.
78. 78 Kapelari, K., Kohle, J., Kotzot, D., et al. Iron supplementation associated with loss of phenotype in autosomal dominant hypophosphatemic rickets. J Clin Endocrinol Metab 100:9 (2015), 3388–3392.
79. 79 Lorenz-Depiereux, B., Bastepe, M., Benet-Pages, A., et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:11 (2006), 1248–1250.
80. 80 Feng, J.Q., Ward, L.M., Liu, S., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:11 (2006), 1310–1315.
81. 81 Levy-Litan, V., Hershkovitz, E., Avizov, L., et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86:2 (2010), 273–278.
82. 82 Rutsch, F., Ruf, N., Vaingankar, S., et al. Mutations in ENPP1 are associated with ‘idiopathic’ infantile arterial calcification. Nat Genet 34:4 (2003), 379–381.
83. 83 Bianco, P., Robey, P., Diseases of bone and the stromal cell lineage. J Bone Miner Res 14:3 (1999), 336–341.
84. 84 Bhattacharyya, N., Wiench, M., Dumitrescu, C., et al. Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res 27:5 (2012), 1132–1141.
85. Riminucci, M., Collins, M.T., Fedarko, N.S., et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:5 (2003), 683–692.
86. 86 Heike, C.L., Cunningham, M.L., Steiner, R.D., et al. Skeletal changes in epidermal nevus syndrome: does focal bone disease harbor clues concerning pathogenesis?. Am J Med Genet A 139A:2 (2005), 67–77.
87. 87 Moreira, A.I., Ferreira, G., Santos, M., et al. Epidermal nevus syndrome associated with hypophosphatemic rickets. Dermatol Online J, 16(9), 2010, 14.
88. 88 White, K.E., Cabral, J.M., Davis, S.I., et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76:2 (2005), 361–367.
89. 89 Shigematsu, T., Kazama, J.J., Yamashita, T., et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:2 (2004), 250–256.
90. 90 Isakova, T., Xie, H., Yang, W., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:23 (2011), 2432–2439.
91. 91 Nakayama, M., Kaizu, Y., Nagata, M., et al. Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study. BMC Nephrol 14:22 (2013), 1–9.
92. 92 Gutierrez, O.M., Januzzi, J.L., Isakova, T., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:19 (2009), 2545–2552.
93. 93 Topaz, O., Shurman, D.L., Bergman, R., et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:6 (2004), 579–581.
94. 94 Benet-Pages, A., Orlik, P., Strom, T.M., et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:3 (2005), 385–390.
95. 95 Ichikawa, S., Imel, E.A., Kreiter, M.L., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Musculoskelet Neuronal Interact 7:4 (2007), 318–319.
96. 96 Frishberg, Y., Topaz, O., Bergman, R., et al. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J Mol Med (Berl) 83:1 (2005), 33–38.
97. 97 Folsom, L.J., Imel, E.A., Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action. Curr Osteoporos Rep 13:2 (2015), 78–87.
98. 98 Burkes, E.J. Jr., Lyles, K.W., Dolan, E.A., et al. Dental lesions in tumoral calcinosis. J Oral Pathol Med 20:5 (1991), 222–227.